News & Updates
-
Lisa’s Letter – July Newsletter
Summer, greetings to all our big-hearted friends As July approaches, our focus is already on the fall and preparing for some major events, including our annual…
-
Hypertrophic Cardiomyopathy Care Centers
What is a Center of Excellence (COE)? A Center of Excellence is a team of specialists who provide high-quality care to patients with a specific disease.…
-
Pro Publica Releases Results of FDA Investigation
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of…
-
Alnylam Receives European Commission Approval for AMVUTTRA® (Vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
EC has granted approval for the treatment of ATTR-CM as an additional indication for AMVUTTRA® (vutrisiran) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi)…
-
Alnylam Announces FDA Approval of AMVUTTRA® (Vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults. AMVUTTRA is an RNAi therapeutic that works upstream…
-
HCM in Pregnancy
Pregnancy is a stress on the body even for healthy people. When we have a serious disease, we tend to have even more questions. As long…
-
Decisions in HCM: My Risk Estimate Was Wrong!
by Gordon Fox: 5th in a series You’ve been told that you had a high risk – say, 5% – of something dangerous, like a lethal…
-
Lisa’s Letter – June Newsletter
June 2025 is upon us and with it comes a great deal of mixed emotions for me and the basis of the founding of HCMA. Origin…
-
June’s Topic Is Staying Fit with HCM
There needs to be more clarity about exercise for HCM patients. Some doctors say, “don’t do anything physical,” and others say, “do whatever you want.” We…
-
Legislative Advocacy Updates June 2025
Nevada Adopts Component of Children’s Cardiac Safety Bill introduced by HCMA Legislative Advocate Jane Grossman Nevada HCMA Legislative State Champion Jane Grossman helped introduce an essential…
-
Cytokinetics Announces Positive Topline Results from MAPLE-HCM
Trial Studies Aficamten in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from MAPLE-HCM (Metoprolol…
-
Decisions in HCM: Where Do Risk Estimates Come From?
by Gordon Fox: 4th in a series Risk is estimated from data Risk estimates come from data on patients. The fact that the numbers are “estimates”…
